Fierce Pharma

MAY 12, 2023

As pharma fights IRA, Senate moves forward basket of bills aimed at lower drug prices aliu Fri, 05/12/2023 - 10:48

Pharma 299

Pharma 299

Fierce Pharma

MAY 11, 2023

After Shkreli's run in with the law, Pharma Bro's former company Vyera files for bankruptcy fkansteiner Thu, 05/11/2023 - 11:06

Pharma 299

Pharma 299

Fierce Pharma

APRIL 3, 2023

Apellis Pharma and its rare disease, eyecare drugs draw takeover interest: Bloomberg zbecker Mon, 04/03/2023 - 11:00

Pharma 286

Pharma 286

Fierce Pharma

MAY 8, 2023

Pfizer, AstraZeneca run it back in IDEA Pharma's annual innovation rankings kdunleavy Mon, 05/08/2023 - 10:21

Pharma 279

Pharma 279

Fierce Pharma

MAY 16, 2023

Wyden blasts Big Pharma for tax ploys and lack of cooperation in probe kdunleavy Tue, 05/16/2023 - 10:51

Pharma 279

Pharma 279

Fierce Pharma

APRIL 20, 2023

The Top Line': How Pfizer became the first in Big Pharma history to break $100B in sales, plus this week's headlines tcarey Thu, 04/20/2023 - 14:46

Sales 299

Sales Pharma 299

Fierce Pharma

MARCH 16, 2023

Novo Nordisk hit with two-year suspension from UK pharma group after online marketing breaches fkansteiner Thu, 03/16/2023 - 09:00

Marketing 279

Marketing Pharma 279

Fierce Pharma

JUNE 12, 2024

As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target | As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has (..)

Pharma 344

Pharma 344

Fierce Pharma

FEBRUARY 5, 2024

After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.

Leads 306

Leads 306

Fierce Pharma

JANUARY 31, 2023

Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better kdunleavy Tue, 01/31/2023 - 10:58

Sales 340

Sales 340

Fierce Pharma

JANUARY 9, 2023

in COVID vaccine sales last year, projects at least $5B in 2023. Mon, 01/09/2023 - 10:34. JPM23: Moderna reaped $18.4B

Sales 328

Sales 328

Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.

Biopharma 312

Biopharma Pharma 312

Fierce Pharma

JANUARY 5, 2024

The last few days of 2023 and the beginning of 2024 featured a flurry of dealmaking by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies | A flurry of deals were inked by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies.

Pharma 243

Pharma 243

Fierce Pharma

APRIL 12, 2024

Davis, 57, received a 9% bump in pay in 2023 to $20.3 . | Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. million, according to the company’s proxy filing.

Biopharma 293

Biopharma 293

Fierce Pharma

FEBRUARY 1, 2024

With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. billion in 2022 and $55.1 billion in 2021.

Sales 312

Sales 312

Fierce Pharma

FEBRUARY 1, 2024

As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues | As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023.

Sales 289

Sales Pharma 289

Fierce Pharma

FEBRUARY 20, 2024

AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall.

Pharma 299

Pharma 299

Fierce Pharma

NOVEMBER 6, 2024

Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report kdunleavy Wed, 11/06/2024 - 09:23

289

289

Fierce Pharma

SEPTEMBER 7, 2023

Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years.

Biopharma 338

Biopharma Pharma 338

Fierce Pharma

OCTOBER 2, 2023

After laying out a goal to launch four new drugs in 2023, Eli Lilly has run into yet another regulatory snag. | The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during the inspection of a third-party contract manufacturing organization.

FDA 296

FDA Manufacturing 296

Fierce Pharma

JANUARY 8, 2024

The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity.

Prospecting 302

Prospecting Biopharma Pharma Healthcare 302

Fierce Pharma

NOVEMBER 6, 2023

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to a | BioNTech has slashed its estimate of 2023 revenue by 20%, now expecting it to reach 4 billion euros ($4.3

Sales 286

Sales 286

Fierce Pharma

FEBRUARY 7, 2024

With the previous year in the rearview and exciting developments already in the mix for 2024, Novo Nordisk’s CEO is taking home a cool 13% raise for his performance in 2023.

246

246

Fierce Pharma

SEPTEMBER 19, 2023

Novo Nordisk’s shares continued to trend downward Tuesday after reports surfaced that the FDA had recently flagged manufacturing shortfalls at the Danish drugmaker’s Clayton, North Carolina product | After inspecting Novo’s Clayton, North Carolina, facility between July 6 and July 13, 2023, the FDA officially chided the company for a pair of quality (..)

FDA 328

FDA Manufacturing Pharma 328

Fierce Pharma

JANUARY 31, 2024

billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo. But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to join the battle in 2024.

Sales 317

Sales Pharma 317

Fierce Pharma

FEBRUARY 12, 2024

With a patent feud settled and its approval application back at the FDA’s desk, Sweden’s Xspray Pharma believes it's on track to launch its first commercial product late this summer.

FDA 304

FDA Pharma 304

Fierce Pharma

SEPTEMBER 12, 2023

Xspray Pharma, before receiving an FDA slapdown in July, had expected to launch its competitor to Bristol Myers Squibb’s leukemia blockbuster Sprycel within the second half of 2023. Xspray and BMS have settled patent litigation around their potential rivals Dasynoc and Sprycel, Xspray said Tuesday.

FDA 290

FDA Pharma 290

Fierce Pharma

JANUARY 25, 2024

Samsung Biologics tallied an “exceptional” year in 2023. . | The FDA will convene an advisory committee to discuss Johnson & Johnson and Legend's Carvykti filing in earlier multiple myeloma. AstraZeneca has won a world-first approval for its rare blood disorder add-on therapy in Japan. And more.

FDA 244

FDA Pharma 244

Fierce Pharma

DECEMBER 22, 2023

Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 350

Biopharma 350

Fierce Pharma

JANUARY 9, 2024

Pfizer knows it had a bad year in 2023. Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Speaking to reporters at the 2024 J.P.

Healthcare 349

Healthcare Healthcare 349

Fierce Pharma

FEBRUARY 8, 2024

billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014.

321

321

Fierce Pharma

MARCH 20, 2024

Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion) for 2023, coming up short of expectations. Sales came to 1.5 billion euros ($1.6 billion euros ($4.1

Sales 336

Sales 336

Fierce Pharma

APRIL 5, 2024

million in 2023, which was an increase of 30% from her $15.9 Vertex CEO Reshma Kewalramani, M.D., million pay in 2022.

355

355

Fierce Pharma

MARCH 25, 2024

In 2023, Eli Lilly CEO David Ricks received a 24% boost in pay from $21.4 million to $26.6 The increase coincides with the company's booming sales.

Sales 359

Sales 359

Fierce Pharma

JANUARY 25, 2024

Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing trend by charting what it called an “exceptional" pe | Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing (..)

Manufacturing 262

Manufacturing 262

Fierce Pharma

AUGUST 7, 2024

As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S.

FDA 283

FDA Marketing 283

Fierce Pharma

OCTOBER 13, 2023

The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again. | The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again.

Sales 311

Sales 311